Physician profile
Brian B Le
NPI 1316969462
$6,668.94
in general payments reported to CMS, 2019-2025
22 companies · $736 in 2025
The $736 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $126 · 2021: $868 · 2022: $924 · 2023: $1,237 · 2024: $2,493 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,854.48 | 2019-2025 | Hydrus Microstent, Clareon, Clareon Panoptix Pro |
| Sight Sciences, INC. | $683.63 | 2021-2025 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $567.54 | 2019-2023 | Tecnis Iol, Tecnis Iol |
| Bausch & Lomb Americas INC. | $476.30 | 2022-2025 | Vyzulta, Lotemax Sm, Miebo |
| Beaver-Visitec International, INC. | $445.92 | 2021-2023 | |
| Allergan, INC. | $293.77 | 2019-2021 | |
| Abbvie INC. | $192.82 | 2022-2025 | |
| Harrow Eye, LLC | $185.39 | 2023-2025 | Iheezo, Vevye |
| Rxsight INC | $182.54 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Astellas Pharma US INC | $136.02 | 2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $130.29 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $95.79 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $91.26 | 2019-2021 | |
| Glaukos Corporation | $69.83 | 2023-2024 | Idose |
| Oyster Point Pharma, INC. | $58.68 | 2022-2024 | Ryzumvi, Tyrvaya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $45.31 | 2024-2025 | Streamline, Kahook Dual Blade, Clearpath |
| Novartis Pharmaceuticals Corporation | $44.89 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $32.25 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $31.47 | 2020-2021 | |
| Notal Vision, INC. | $19.68 | 2019 | |
| Thea Pharma INC. | $19.32 | 2024 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.